[{"id":"79853e3c-57e0-4bdc-a5ec-927f20acf680","acronym":"ALKOVE-1","url":"https://clinicaltrials.gov/study/NCT05384626","created_at":"2022-05-20T17:58:30.523Z","updated_at":"2024-07-02T16:34:36.881Z","phase":"Phase 1/2","brief_title":"A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)","source_id_and_acronym":"NCT05384626 - ALKOVE-1","lead_sponsor":"Nuvalent Inc.","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • neladalkib (NVL-655)"],"overall_status":"Recruiting","enrollment":" Enrollment 470","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-06-10"}]